Amgen Discusses Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting

On Thursday, March 13, 2008, Amgen presented the benefits and risks of Erythropoiesis-stimulating Agents (ESAs) in cancer patients with anemia due to concomitantly administered chemotherapy at a meeting with the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC).